Harmony Biosciences Holdings Inc
For the period ended Sep 30, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 29, 2024
HRMY$33.55-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
| · · · · · · · · · · · · | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended September 30, · · Nine Months Ended September 30, | |||||||||||
| · 2024 · 2023 · 2024 · 2023 | |||||||||||
| Net product revenue | | $186,038 | | $160,268 | | $513,467 | | $413,610 | |||
| Cost of product sold | | 42,778 | | 32,296 | | 102,406 | | 78,084 | |||
| Gross profit | | 143,260 | | 127,972 | | 411,061 | | 335,526 | |||
| Operating expenses: | | | | | |||||||
| Research and development | | 25,387 | | 17,499 | | 111,159 | | 45,757 | |||
| Sales and marketing | | 27,576 | | 23,418 | | 83,316 | | 70,518 | |||
| General and administrative | | 28,587 | | 22,546 | | 81,487 | | 67,417 | |||
| Total operating expenses | | 81,550 | | 63,463 | | 275,962 | | 183,692 | |||
| Operating income | | 61,710 | | 64,509 | | 135,099 | | 151,834 | |||
| Loss on debt extinguishment | | — | | (9,766) | | — | | (9,766) | |||
| Other (expense) income, net | | (124) | | (5) | | (228) | | (34) | |||
| Interest expense | | | (4,348) | | | (7,012) | | | (13,287) | | (18,961) |
| Interest income | | 4,932 | | 4,106 | | 14,065 | | 10,634 | |||
| Income before income taxes | | 62,170 | | 51,832 | | 135,649 | | 133,707 | |||
| Income tax expense | | (16,077) | | (13,371) | | (39,631) | | (31,461) | |||
| Net income | | $46,093 | | $38,461 | | $96,018 | | $102,246 | |||
| Unrealized (loss) income on investments | | 733 | | 6 | | 497 | | (365) | |||
| Comprehensive income | | $46,826 | | $38,467 | | $96,515 | | $101,881 | |||
| EARNINGS PER SHARE: | | | | | |||||||
| Basic | | $0.81 | | $0.64 | | $1.69 | | $1.71 | |||
| Diluted | | $0.79 | | $0.63 | | $1.66 | | $1.68 | |||
| Weighted average number of shares of common stock - basic | | 56,870,234 | | 59,863,102 | | 56,815,167 | | 59,856,941 | |||
| Weighted average number of shares of common stock - diluted | | 58,103,963 | | 60,681,676 | | 57,754,016 | | 60,892,992 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.